KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zoetis (ZTS) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Zoetis (ZTS) over the last 14 years, with Q4 2025 value amounting to $161.0 million.

  • Zoetis' Capital Expenditures fell 2546.3% to $161.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $621.0 million, marking a year-over-year decrease of 519.08%. This contributed to the annual value of $621.0 million for FY2025, which is 519.08% down from last year.
  • Zoetis' Capital Expenditures amounted to $161.0 million in Q4 2025, which was down 2546.3% from $133.0 million recorded in Q3 2025.
  • Zoetis' Capital Expenditures' 5-year high stood at $223.0 million during Q1 2023, with a 5-year trough of $77.0 million in Q1 2021.
  • For the 5-year period, Zoetis' Capital Expenditures averaged around $153.5 million, with its median value being $151.5 million (2022).
  • As far as peak fluctuations go, Zoetis' Capital Expenditures soared by 9391.3% in 2023, and later plummeted by 3721.97% in 2024.
  • Zoetis' Capital Expenditures (Quarter) stood at $168.0 million in 2021, then rose by 1.79% to $171.0 million in 2022, then grew by 15.79% to $198.0 million in 2023, then rose by 9.09% to $216.0 million in 2024, then decreased by 25.46% to $161.0 million in 2025.
  • Its Capital Expenditures stands at $161.0 million for Q4 2025, versus $133.0 million for Q3 2025 and $178.0 million for Q2 2025.